Literature DB >> 29719436

Variation in routine follow-up care after curative treatment for head-and-neck cancer: a population-based study in Ontario.

K E Brennan1, S F Hall2,3, T E Owen3, R J Griffiths4, Y Peng5.   

Abstract

Background: The actual practices of routine follow-up after curative treatment for head-and-neck cancer are unknown, and existing guidelines are not evidence-based.
Methods: This retrospective population-based study used administrative data to describe 5 years of routine follow-up care in 3975 head-and-neck cancer patients diagnosed between 2007 and 2012 in Ontario.
Results: The mean number of visits per year declined during the follow-up period (from 7.8 to 1.9, p < 0.001). The proportion of patients receiving visits in concordance with guidelines ranged from 80% to 45% depending on the follow-up year. In at least 50% of patients, 1 head, neck, or chest imaging test was performed in the first follow-up year; that proportion subsequently declined (p < 0.001). Factors associated with follow-up practices included comorbidity, tumour site, treatment, geographic region, and physician specialty (p < 0.05). Conclusions: Given current practice variation and the absence of an evidence-based standard, the challenge in identifying a single optimal follow-up strategy might be better addressed with a harmonized approach to providing individualized follow-up care.

Entities:  

Keywords:  Head-and-neck cancer; imaging; practice variation; routine follow-up

Mesh:

Year:  2018        PMID: 29719436      PMCID: PMC5927791          DOI: 10.3747/co.25.3892

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  32 in total

1.  Geographical variation in surveillance strategies after curative-intent surgery for upper aerodigestive tract cancer.

Authors:  Frank E Johnson; Michael H Johnson; Marc F Clemente; Randal C Paniello; Katherine S Virgo
Journal:  Ann Surg Oncol       Date:  2006-06-21       Impact factor: 5.344

Review 2.  Follow-up strategies for patients treated for non-metastatic colorectal cancer.

Authors:  M Jeffery; B E Hickey; P N Hider
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

3.  The utility of administrative data for measuring adherence to cancer surveillance care guidelines.

Authors:  Gregory S Cooper; Lonni Schultz; Janine Simpkins; Jennifer Elston Lafata
Journal:  Med Care       Date:  2007-01       Impact factor: 2.983

4.  Human papillomavirus and rising oropharyngeal cancer incidence in the United States.

Authors:  Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

5.  Head and neck squamous cell cancers: need for an organised time-bound surveillance plan.

Authors:  Rehan Kazi; Kapila Manikanthan; K A Pathak; Raghav C Dwivedi
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-09-11       Impact factor: 2.503

6.  A population-based study of follow-up care for Hodgkin lymphoma survivors: opportunities to improve surveillance for relapse and late effects.

Authors:  David C Hodgson; Eva Grunfeld; Nadia Gunraj; Lisa Del Giudice
Journal:  Cancer       Date:  2010-07-15       Impact factor: 6.860

7.  Time to first relapse as an outcome and a predictor of survival in patients with squamous cell carcinoma of the head and neck.

Authors:  S F Hall; P A Groome; D Rothwell
Journal:  Laryngoscope       Date:  2000-12       Impact factor: 3.325

8.  Impact of surveillance on survival after laryngeal cancer in the medicare population.

Authors:  David O Francis; Bevan Yueh; Ernest A Weymuller; Albert L Merati
Journal:  Laryngoscope       Date:  2009-12       Impact factor: 3.325

9.  Surveillance patterns after curative-intent colorectal cancer surgery in Ontario.

Authors:  Jensen Tan; Jennifer Muir; Natalie Coburn; Simron Singh; David Hodgson; Refik Saskin; Alex Kiss; Lawrence Paszat; Abraham El-Sedfy; Eva Grunfeld; Craig Earle; Calvin Law
Journal:  Can J Gastroenterol Hepatol       Date:  2014-07-11

Review 10.  Achieving optimal delivery of follow-up care for prostate cancer survivors: improving patient outcomes.

Authors:  Shawna V Hudson; Denalee M O'Malley; Suzanne M Miller
Journal:  Patient Relat Outcome Meas       Date:  2015-03-19
View more
  5 in total

1.  Does the frequency of routine follow-up after curative treatment for head-and-neck cancer affect survival?

Authors:  S F Hall; T Owen; R J Griffiths; K Brennan
Journal:  Curr Oncol       Date:  2019-10-01       Impact factor: 3.677

2.  Characterizing head and neck cancer survivors' discontinuation of survivorship care.

Authors:  Aaron T Seaman; Kristen L Seligman; Khanh K Nguyen; Zaid Al-Qurayshi; Nicholas D Kendell; Nitin A Pagedar
Journal:  Cancer       Date:  2021-08-30       Impact factor: 6.860

Review 3.  Head and neck cancer survivorship consensus statement from the American Head and Neck Society.

Authors:  Neerav Goyal; Andrew Day; Joel Epstein; Joseph Goodman; Evan Graboyes; Scharukh Jalisi; Ana P Kiess; Jamie A Ku; Matthew C Miller; Aru Panwar; Vijay A Patel; Assuntina Sacco; Vlad Sandulache; Amy M Williams; Daniel Deschler; D Gregory Farwell; Cherie-Ann Nathan; Carole Fakhry; Nishant Agrawal
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-11-30

4.  Clinical Characteristics and Predictive Outcomes of Recurrent Nasopharyngeal Carcinoma-A Lingering Pitfall of the Long Latency.

Authors:  Yung-Hsuan Chen; Sheng-Dean Luo; Shao-Chun Wu; Ching-Nung Wu; Tai-Jan Chiu; Yu-Ming Wang; Yao-Hsu Yang; Wei-Chih Chen
Journal:  Cancers (Basel)       Date:  2022-08-04       Impact factor: 6.575

5.  Do doctors who order more routine medical tests diagnose more cancers? A population-based study from Ontario Canada.

Authors:  Stephen F Hall; Colleen Webber; Patti A Groome; Christopher M Booth; Paul Nguyen; Yvonne DeWit
Journal:  Cancer Med       Date:  2019-01-04       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.